Gene Therapy
Therapeutic modification of genes to treat disease, enhance function, or potentially extend lifespan.
Evidence Summary
Gene therapy is now established clinical medicine for specific genetic and hematologic diseases, with dozens of products approved by regulators and administered only in regulated settings. Longevity applications remain preclinical and investigational. The clearest proof-of-principle is telomerase gene therapy: a single AAV vector expressing TERT given to normal mice raised median lifespan by about 24% when started in adulthood (1 year of age) and about 13% when started in old age (2 years), with improved insulin sensitivity, bone and neuromuscular measures and no increase in cancer (Bernardes de Jesus et al., EMBO Molecular Medicine, 2012). Work through 2024-2025 extended this: a 2025 study showed AAV or extracellular-vesicle delivery of the circular RNA circHERC1 reactivated telomerase and improved cognition and physical performance in aged mice (Cui et al., Science Advances, 2025), and recent reviews map telomerase, klotho, follistatin and epigenetic-reprogramming approaches alongside their risks (Dunn et al., Subcellular Biochemistry, 2024; Sanada et al., Frontiers in Cardiovascular Medicine, 2025). Telomerase is double-edged: the telomerase inhibitor imetelstat was approved in 2024 for myelodysplastic syndromes, a reminder that boosting telomerase carries a theoretical cancer risk (Keam, Drugs, 2024). No anti-aging gene therapy has been validated in human trials; offshore clinics and self-experimentation are not evidence.
Evidence Scale
Mechanism of Action
Four broad strategies. Gene addition delivers a working or beneficial gene with a viral vector, usually adeno-associated virus (AAV) - longevity research examples include TERT (telomerase), klotho and follistatin. Gene editing (CRISPR-Cas and base/prime editors) corrects or disables a target sequence. Gene silencing uses antisense oligonucleotides or siRNA to lower a harmful transcript. Epigenetic (partial) reprogramming transiently expresses Yamanaka factors to reset age-related marks without changing the DNA sequence. Each aims at the root molecular cause rather than downstream symptoms.
Who Is This For?
Approved indications: specific inherited and hematologic diseases. Longevity use is experimental and appropriate only within a registered clinical trial. A cutting-edge, investigational intervention for healthy aging.
Protocol & Dosing
Dose
Highly specific to therapy and target.
Frequency
Single to periodic
Duration
Usually single administration
Protocol Summary
Highly specific to the approach and target. Approved gene therapies are disease-specific, given as a one-time or periodic treatment inside regulated clinical programs with long-term monitoring. Experimental longevity protocols (for example AAV-delivered telomerase, klotho or follistatin) have no validated human dose, schedule or safety window and are offered only through clinical trials or unregulated offshore clinics. Peak Human does not provide anti-aging gene therapy; this entry is educational information, not medical advice.
Interactions & Precautions
Contraindications
- Varies by specific therapy
- Active or high-risk malignancy (telomerase-activating approaches)
- Prior neutralizing immunity to the viral vector
Potential Risks
- •Off-target or insertional effects
- •Immune reaction to the viral vector
- •Theoretical cancer risk with telomerase activation
- •Unknown long-term consequences
- •High cost and limited oversight offshore
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Approved gene therapies are highly effective for the specific genetic conditions they target. For longevity, the human evidence is not there yet - the compelling lifespan and healthspan data are in mice. Counsel patients that offshore longevity gene therapy lacks regulatory oversight, published safety data and validated dosing, and that telomerase-activating approaches carry a theoretical cancer concern. Biological-age and telomere testing are how any future effect would be measured. Notable programs include work from Maria Blasco (CNIO), George Church and Rejuvenate Bio.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Latest Evidence
2024-2026: where gene therapy for aging actually stands
Gene therapy has become real clinical medicine: dozens of gene and cell therapies are now approved for inherited and blood diseases and are given only in regulated centres. Using it to slow aging is a separate, still-experimental question. The clearest proof-of-principle came from telomerase: a single adeno-associated virus (AAV) carrying the TERT gene raised the median lifespan of normal mice by about 24% when given in adulthood and about 13% when given in old age, alongside better insulin sensitivity, bone and neuromuscular function - and, notably, no increase in cancer (Bernardes de Jesus et al., 2012).
Work through 2024-2025 has built on this. A 2025 study showed that delivering the circular RNA circHERC1 by AAV or extracellular vesicles reactivated telomerase, lengthened telomeres and improved cognition and physical performance in aged mice (Cui et al., Science Advances, 2025). Recent reviews map the leading longevity targets - telomerase, klotho, follistatin and epigenetic reprogramming - together with their hurdles (Dunn et al., 2024; Sanada et al., 2025). Telomerase is genuinely double-edged: the telomerase inhibitor imetelstat was approved in 2024 to treat a blood cancer, underscoring that switching telomerase on carries a theoretical cancer risk (Keam, 2024).
Important context: every anti-aging result here is preclinical - in cells and animals, not people. There are no validated human anti-aging gene therapies, no established dose or safety window, and the main risks (off-target effects, immune reactions to the vector, insertional mutagenesis, and a theoretical cancer risk from telomerase activation) are real. Approved gene therapies target specific genetic diseases, not aging. Offshore clinics and self-experimentation are not evidence. Peak Human does not offer anti-aging gene therapy. Educational information, not medical advice.
Preclinical · AAV-TERT gene therapy in mice · vs untreated controls
Median lifespan increase after telomerase (AAV-TERT) gene therapy
Source: Bernardes de Jesus et al., EMBO Molecular Medicine, 2012 - single AAV vector expressing TERT in normal mice; bars show the increase in median lifespan versus untreated controls, with no increase in cancer reported. Preclinical (mouse) data; not established in humans.
Related on Peak Human
Partial Reprogramming
Epigenetic reprogramming: the AAV-based rejuvenation approach, with its own preclinical lifespan data.
Telomeric DDR Inhibition
Another telomere-focused longevity strategy in the Database.
Stem Cell Therapy
A related regenerative, cell-based approach with a clinical evidence base.
Diagnostic Testing
Biological-age and biomarker testing: how any rejuvenation effect would be measured.
Longevity Research Insider
Weekly Peak Human Brief on new longevity research.
Key references: Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer - EMBO Molecular Medicine (2012) · circHERC1, a telomerase activator - Science Advances (2025) · Telomerase-Mediated Anti-Ageing Interventions - Subcellular Biochemistry (2024) · Targeting the hallmarks of aging: mechanisms and therapeutic opportunities - Frontiers in Cardiovascular Medicine (2025) · Imetelstat: First Approval - Drugs (2024)
Cost & Access
Cost Range
$$$$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
